Dr. Azad on the Design of the ARCHES Trial in mHSPC

Video

Arun Azad, PhD, discusses the design of the ​phase 3ARCHES trial in metastatic hormone-sensitive prostate cancer.

Arun Azad, PhD, an associate professor at Peter MacCallum Cancer Centre and the University of Melbourne; fellow at Victorian Cancer Agency; and chair of the ANZUP Cancer Trials Group Translational, discusses the design of the ​phase 3ARCHES trial in metastatic hormone-sensitive prostate cancer (mHSPC).

​The ARCHES study randomized patients with mHSPC to receive androgen deprivation therapy with enzalutamide (Xtandi) or placebo.

The trial was designed to evaluate ​all men with mHSPC ​rather than evaluating 1 specific subtype, says Azad.

Notably, the study included men with low​- and high​-volume mHSPC, ​men with newly diagnosed and relapsed​/refractory ​mHSPC, and ​men who previously received docetaxel.

Additionally, ARCHES was a multicenter, international study​; thus, the data are widely applicable, Azad concludes.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,